Clear, engaging, and practical updates on clinical psychiatry.
Earn CME for listening to the podcast with a Podcast CME Subscription.
Listen for free here or using Apple Podcasts and Spotify.
Can we treat depression by targeting inflammation? Do SSRIs for post-stroke depression increase the risk of second intracranial hemorrhage? And how effective is the new combination treatment, olanzapine/samidorphan, for mitigating antipsychotic-induced weight gain? We will answer these questions in this Hospital Psychiatry Research Update Extravaganza!
Omega-3 fatty acids do treat depression, but not with the formulations that are commonly found on the shelves. Here we point you in the right direction, and give a winding origin story of these essential fatty acids.
Do antipsychotics have neurotoxic effects in youth? In this episode, we’ll be banging the drum of caution about antipsychotic use in children and adolescents.
Lybalvi combines olanzapine with the opioid blocker samidorphan in hopes of curbing the weight gain on that antipsychotic. Here, we look at how well it works.
The pharmaceutical industry created 3 myths around opioids: “Pain as the fifth vital sign,” the less-than-1% rate of addiction, and the diagnosis of pseudoaddiction. Inside, we look at what is true and what is exaggeration in these claims.
Psychoanalyst Dan Buie, MD, describes 5 deficits that cause great suffering for people with personality disorders and how to work with them in therapy.